Details of the Drug

General Information of Drug (ID: DMCDMFP)

Drug Name
TT-223
Synonyms
E1-INT; GLP1-INT; Islet cell neogenesis therapy, Transition Therapeutics; Islet neogenesis therapy, Transition; Diabetes therapy, Waratah/MGH; EGF-INT, Transition Therapeutics; Glucagon-like peptide + gastrin analog, Transition; INT (diabetes), Waratah/MGH; Epidermal growth factor analog + TT-223 (diabetes), Transition; Islet neogenesis therapy (GLP-1, gastrin), Transition; Glucagon-like peptide + TT-223, (diabetes) Transition
Indication
Disease Entry ICD 11 Status REF
Type-1 diabetes 5A10 Phase 2 [1]
Cross-matching ID
TTD ID
D02FYE

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastrin/cholecystokinin type B receptor (CCKBR) TTVFO0U GASR_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Type-1 diabetes
ICD Disease Classification 5A10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Gastrin/cholecystokinin type B receptor (CCKBR) DTT CCKBR 6.53E-01 1.00E-03 4.05E-03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00743002) A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione. U.S. National Institutes of Health.
2 The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98.